TrialClinical and translational science2025

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT-787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial.

Thomas Capozza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.